Eculizumab and SB12 population PK
Reference paper ↗A two-compartment population PK model representing eculizumab or SB12 disposition, body-weight effects, disease-specific central volume, concentration, and cumulative exposure.
- Therapeutic
- Eculizumab or SB12
- Modality
- Monoclonal antibody
- Target
- Complement C5
- Disease
- Healthy participants and paroxysmal nocturnal hemoglobinuria
- Model type
- PopPK, PKPD
Complete model workspace
Checking workspace access…
- Parameters
- 10
- States
- 4
- Equations
- 4
- Derived outputs
- 19
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Healthy 300 mg IV single-dose PK/PD
How do body weight and disease context change eculizumab or SB12 concentration and exposure? Explore this intervention regimen through Central eculizumab or SB12 concentration, Peripheral concentration, Cumulative exposure, Individual clearance.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–672 hour; step 6
| Input | Default | Available range |
|---|---|---|
| PK clearance | 0.0174 L/h | 0.0087–0.0261 L/h |
| Central distribution volume — healthy participants | 3.47 L | 1.735–5.205 L |
| Central distribution volume — PNH | 5.68 L | 2.84–8.52 L |
| PK intercompartmental clearance | 0.0134 L/h | 0.0067–0.0201 L/h |
| PK peripheral distribution volume | 0.79 L | 0.395–1.185 L |
Expected readouts
Central eculizumab or SB12 concentration · Peripheral concentration · Exposure (AUC) (ug*h/mL) · Systemic clearance
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 10 declared model parameters.
More key parameters (1)
How the model represents the biology
A two-compartment population PK model representing eculizumab or SB12 disposition, body-weight effects, disease-specific central volume, concentration, and cumulative exposure.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: C5 binding or inhibition, complement suppression, LDH or hemolysis response, efficacy, and a biosimilar difference are not represented; this release is PK-only.
Modeled relationships (6)
- IV antibody bolus → Central exposure: IV input (flow)
- Central exposure ↔ Peripheral pool: distribution (reversible exchange)
- Central exposure → Systemic clearance: systemic CL (loss)
- Weight + disease context → Systemic clearance: scales CL (modulation)
- Weight + disease context → Central exposure: sets volume (modulation)
- Central exposure → Cumulative exposure: integrates C (production)
Modeled relationships: IV antibody bolus to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Systemic clearance: systemic CL (loss); Weight + disease context to Systemic clearance: scales CL (modulation); Weight + disease context to Central exposure: sets volume (modulation); Central exposure to Cumulative exposure: integrates C (production).
Primary readouts: Central antibody concentration; Peripheral concentration; Cumulative exposure; Clearance.
Related models
Research use only — not for patient-specific prediction or dosing advice.
